P/E ratio for Pulmatrix (PULM)
P/E ratio as of June 2024 (TTM): -0.4021
According to Pulmatrix's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.402062. At the end of 2022 the company had a P/E ratio of -0.7106.
P/E ratio history for Pulmatrix from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.7106 | -30.15% |
| 2021 | -1.02 | -45.15% |
| 2020 | -1.86 | 221.39% |
| 2019 | -0.5772 | 32.51% |
| 2018 | -0.4356 | -71.21% |
| 2017 | -1.51 | 379.5% |
| 2016 | -0.3155 | -45.78% |
| 2015 | -0.5819 | -74.56% |
| 2014 | -2.29 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Pieris Pharmaceuticals PIRS | -23.5 | 5,754.94% | 🇺🇸 USA |
 OPKO Health
OPK | -4.78 | 1,088.32% | 🇺🇸 USA |
 Blueprint Medicines
BPMC | -11.6 | 2,783.66% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.